Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: State of the art

Endocrine-Related Cancer

Volumn 21, Issue 3, 2014, Pages

  De Mestier, Louis ^a   Dromain, Clarisse ^b   D'Assignies, Gaspard ^c   Scoazec, Jean Yves ^d   Lassau, Nathalie ^b   Lebtahi, Rachida ^c   Brixi, Hedia ^a   Mitry, Emmanuel ^e   Guimbaud, Rosine ^f   Courbon, Frédéric ^g   D'Herbomez, Michèle ^h   Cadiot, Guillaume ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c BEAUJON HOSPITAL   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e INSTITUT CURIE   (France)

^f TOULOUSE UNIVERSITY HOSPITAL   (France)

^g INSTITUT CLAUDIUS REGAUD   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Biomarker; Contrast enhanced imaging; CT scan; Evaluation; Isotopic imaging; MRI; Neuroendocrine tumors; Prognosis; Progression; Response; Targeted therapies; Ultrasonography

Indexed keywords

DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; OCTREOTIDE; STREPTOZOCIN; SUNITINIB;

CANCER MORPHOLOGY; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; EVALUATION STUDY; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; NEUROENDOCRINE TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PHYSICAL DISEASE BY BODY FUNCTION; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR GROWTH; ANIMAL; DISEASE COURSE; GASTROINTESTINAL NEOPLASMS; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMORS; PATHOLOGY;

ANIMALS; DISEASE PROGRESSION; GASTROINTESTINAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS;

EID: 84903604456     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0365     Document Type: Review

References (120)

1. Abgral R, Leboulleux S, Déandreis D, Aupérin A, Lumbroso J, Dromain C, Duvillard P, Elias D, de Baere T, Guigay J et al. 2011 Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging. Journal of Clinical Endocrinology and Metabolism 96 665-671. (doi:10.1210/jc.2010-2022)
2. Abou-Saif A, Gibril F, Ojeaburu JV, Bashir S, Entsuah LK, Asgharian B & Jensen RT 2003 Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer 98 249-261. (doi:10.1002/cncr.11473) (Pubitemid 36828447)
3. Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, Ardill J, Johnston BT, Poston G, Rees M et al. 2009 Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocrine-Related Cancer 16 885-894. (doi:10.1677/ERC-09-0042)
4. Ambrosini V, Campana D, Tomassetti P & Fanti S 2012 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. European Journal of Nuclear Medicine and Molecular Imaging 39 S52-S60.(doi:10.1007/s00259-011-1989- 4)
5. Andersson E, Swärd C, Stenman G, Ahlman H & Nilsson O 2009 High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids. Endocrine-Related Cancer 16 953-966. (doi:10.1677/ERC-09-0052)
6. Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose K-J, Scherag A, Hahmann M, Müller H-H & Barth P 2008 Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clinical Gastroenterology and Hepatology 6 820-827. (doi:10.1016/j.cgh. 2008.02.052)
7. Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, Schulz S, Boneu A, Guimbaud R & Buscail L 2008 Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. Journal of Clinical Oncology 26 963-970. (doi:10.1200/JCO.2007.12.7431) (Pubitemid 351398091)
8. Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, Zilembo N, Di Bartolomeo M, Seregni E & Bombardieri E 1999 Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 86 858-865. (doi:10.1002/(SICI)1097-0142(19990901)86:5!858::AIDCNCR23O3.0.CO;2-8)
9. Baudin E, Wolin EM, Castellano D, Kaltsas G, Panneerselvam A, Saletan S, Yao JC & Gross D 2011 Correlation of PFS and chromogranin A and 5-hydroxyindoleacetic acid levels in patients with advanced neuroendocrine tumors: phase 3 RADIANT-2 study results. Annals of Oncology 22 v1-v144. (doi:10.1093/annonc/mdr284)
10. Bergestuen DS, Aabakken L, Holm K, Vatn M& Thiis-Evensen E 2009 Small intestinal neuroendocrine tumors: prognostic factors and survival. Scandinavian Journal of Gastroenterology 44 1084-1091. (doi:10.1080/00365520903082432)
11. Bhosale P, Shah A, WeiW, Varadhachary G, Johnson V, Shah V & Kundra V 2013 Carcinoid tumours: predicting the location of the primary neoplasm based on the sites of metastases. European Radiology 23 400-407. (doi:10.1007/s00330- 012-2615-y)
12. Blanke CD, Rankin C, Demetri GD, Ryan CW, von MehrenM, Benjamin RS, Raymond AK, Bramwell VHC, Baker LH, Maki RG et al. 2008 Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Journal of Clinical Oncology 26 626-632. (doi:10.1200/JCO.2007.13.4452)
13. Bos R, van der Hoeven JJM, van der Wall E, van der Groep P, van Diest PJ, Comans EFI, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA et al. 2002 Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. Journal of Clinical Oncology 20 379-387. (doi:10.1200/JCO.20.2.379)
14. Boutrus RR, Abi Raad RF, Kuter I, Ancukiewicz M, Roberts L, Solomon N, Ngo T, Borick H, Ryan P, Moy B et al. 2013 Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy. International Journal of Biological Markers 28 17-23. (doi:10.5301/JBM.2012.9580)
15. Braga F, Ferraro S, Mozzi R, Dolci A & Panteghini M 2013 Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase. Clinical Biochemistry 46 148-151. (doi:10.1016/j.clinbiochem.2012.09. 005)
16. Campana D, Nori F, Piscitelli L,Morselli-Labate AM, Pezzilli R, Corinaldesi R & Tomassetti P 2007 Chromogranin A: is it a useful marker of neuroendocrine tumors? Journal of Clinical Oncology 25 1967-1973. (doi:10.1200/JCO.2006.10.1535) (Pubitemid 46972778)
17. Casali PG, Blay J-Y & On behalf of the ESMO/CONTICANET/EUROBONET Consensus Panel of Experts 2010 Soft tissue sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21 v198-v203. (doi:10.1093/annonc/mdq209)
18. Chambers AJ, Pasieka JL, Dixon E & Rorstad O 2008 The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery 144 645-653. (doi:10.1016/j.surg. 2008.06.008)
19. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA & Benjamin RS 2007 Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. Journal of Clinical Oncology 25 1753-1759. (doi:10.1200/JCO.2006.07.3049) (Pubitemid 46797957)
20. Chun YS, Vauthey J-N, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Kaur H, Charnsangavej C et al. 2009 Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. Journal of the AmericanMedical Association 302 2338-2344. (doi:10.1001/jama.2009.1755)
21. Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC et al. 2013 Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound in Medicine & Biology 39 187-210. (doi:10.1016/j.ultrasmedbio.2012.09.002)
22. Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K et al. 2005 Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. British Journal of Cancer 92 94-101. (doi:10.1038/sj.bjc.6602245) (Pubitemid 40188441)
23. Couvelard A, Deschamps L, Ravaud P, Baron G, Sauvanet A, Hentic O, Colnot N, Paradis V, Belghiti J, Bedossa P et al. 2009 Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Modern Pathology 22 273-281. (doi:10.1038/ modpathol.2008.177)
24. Cui Y, Zhang X-P, Sun Y-S, Tang L & Shen L 2008 Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepaticmetastases. Radiology 248 894-900. (doi:10.1148/radiol.2483071407)
25. Danila DC, Fleisher M & Scher HI 2011 Circulating tumor cells as biomarkers in prostate cancer. Clinical Cancer Research 17 3903-3912. (doi:10.1158/1078-0432.CCR-10-2650)
26. D'Assignies G, Couvelard A, Bahrami S, Vullierme M-P, Hammel P, Hentic O, Sauvanet A, Bedossa P, Ruszniewski P & Vilgrain V 2009 Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology 250 407-416. (doi:10.1148/radiol. 2501080291)
27. D'Assignies G, Fina P, Bruno O, Vullierme MP, Paradis V, Sauvanet A, Ruszniewski P & Vilgrain V 2013 High sensitivity of diffusion-weighted MRI for the detection of liver metastases from neuroendocrine tumors compared with T2-weighted and dynamic gadolinium-enhanced MRI, using histological findings as a standard of reference. Radiology 268 390-399. (doi:10.1148/radiol.13121628)
28. Davies AHG, Larsson G, Ardill J, Friend E, Jones L, Falconi M, Bettini R, Koller M, Sezer O, Fleissner C et al. 2006 Development of a diseasespecific quality of life questionnaire module for patients with gastrointestinal neuroendocrine tumours. European Journal of Cancer 42 477-484. (doi:10.1016/j.ejca.2005.10.025)
29. Desar IME, van Herpen CML, van Laarhoven HWM, Barentsz JO, Oyen WJG & van der Graaf WTA 2009 Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treatment Reviews 35 309-321. (doi:10.1016/j.ctrv.2008.12.001)
30. D'Herbomez M, Do Cao C, Vezzosi D, Borzon-Chasot F & Baudin E 2010 Chromogranin A assay in clinical practice. Annales d'Endocrinologie 71 274-280. (doi:10.1016/j.ando.2010.04.004)
31. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Jänicke F & Avril N 2005 Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. Journal of Nuclear Medicine 46 1144-1150. (Pubitemid 43741076)
32. Dreyer C, Hentic O, Zappa M, Hammel P, Bouattour M, Mateescu C, Faivre S, Ruszniewski P & Raymond E 2012 Response evaluation using RECIST and Choi criteria in patients with well-differentiated pancreatic neuroendocrine tumors (PNET) treated with sunitinib or everolimus. ESMO Annual Congress, 28 Sept-2 Oct, Vienna, Austria. Abstract 1163.
33. Dromain C, de Baere T, Baudin E,Galline J, Ducreux M, Boige V, Duvillard P, Laplanche A, Caillet H, Lasser P et al. 2003 MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. American Journal of Roentgenology 180 121-128. (doi:10.2214/ajr.180.1.1800121) (Pubitemid 36008698)
34. Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, Ducreux M, Duvillard P, Elias D, Schlumberger M et al. 2005 Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. Journal of Clinical Oncology 23 70-78. (doi:10.1200/JCO.2005.01.013) (Pubitemid 41702624)
35. Druce MR, Bharwani N, Akker SA, Drake WM, Rockall A & Grossman AB 2010 Intra-abdominal fibrosis in a recent cohort of patients with neuroendocrine ('carcinoid') tumours of the small bowel. QJM : Monthly Journal of the Association of Physicians 103 177-185. (doi:10.1093/qjmed/hcp191)
36. Ducreux M, Seitz J-F, Smith D, O'Toole D, Lepère C, Bitoun L & Mitry E 2012 Efficacy and safety of bevacizumab combined with chemotherapy in the treatment of patients with metastatic well-differentiated duodeno-pancreatic endocrine tumors (BETTER study). Journal of Clinical Oncology 30 (Suppl) 4036.
37. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al. 2009 New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer 45 228-247. (doi:10.1016/j.ejca.2008.10.026)
38. Ekeblad S, Skogseid B, Dunder K, Oberg K & Eriksson B 2008 Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clinical Cancer Research 14 7798-7803. (doi:10.1158/1078-0432.CCR-08-0734)
39. Elias D, Lefevre JH, Duvillard P, Goéré D, Dromain C, Dumont F & Baudin E 2010 Hepatic metastases from neuroendocrine tumors with a 'thin slice' pathological examination: they are many more than you think. Annals of Surgery 251 307-310. (doi:10.1097/SLA.0b013e3181bdf8cf)
40. Faivre S, Zappa M, Vilgrain V, Boucher E, Douillard J-Y, Lim HY, Kim JS, Im S-A, Kang Y-K, Bouattour M et al. 2011 Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. Clinical Cancer Research 17 4504-4512. (doi:10.1158/1078-0432.CCR-10-1708)
41. Faivre S, Ronot M, Dreyer C, Serrate C, Hentic O, Bouattour M, Bruno O, Couvelard A, Vilgrain V & Raymond E 2012 Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. Targeted Oncology 7 127-133. (doi:10.1007/s11523-012-0216-y)
42. Flaherty KT, Rosen MA, Heitjan DF, Gallagher ML, Schwartz B, Schnall MD & O'Dwyer PJ 2008 Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biology & Therapy 7 496-501. (doi:10.4161/cbt.7.4.5624) (Pubitemid 351847022)
43. Fröjd C, Larsson G, Lampic C & von Essen L 2007 Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health and Quality of Life Outcomes 5 18. (doi:10.1186/1477-7525-5-18)
44. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, von Guggenberg E, Bale R & Virgolini IJ 2007 68Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. Journal of Nuclear Medicine 48 508-518. (doi:10.2967/jnumed.106.035667) (Pubitemid 47571404)
45. Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R & Virgolini IJ 2009 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatinreceptor-mediated radionuclide therapy. Journal of Nuclear Medicine 50 1427-1434. (doi:10.2967/jnumed.108. 053421)
46. Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard A-S, Bouriel C, Boucher E & Raoul J-L 2009 Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. Journal of Nuclear Medicine 50 858-864. (doi:10.2967/jnumed.108.057505)
47. Guibal A, Lefort T, Chardon L, Benslama N, Mulé S, Pilleul F, Lombard-Bohas C, Bridal L, Chayvialle JA, Lucidarme O et al. 2013 Contrast-enhanced ultrasound after devascularisation of neuroendocrine liver metastases: functional and morphological evaluation. European Radiology 23 805-815. (doi:10.1007/s00330-012-2646-4)
48. Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ & Stadler WM 2008 Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. Journal of Clinical Oncology 26 4572-4578. (doi:10.1200/JCO. 2007.15.5655)
49. Haug AR, Auernhammer CJ, Wängler B, Schmidt GP, Uebleis C, Göke B, Cumming P, Bartenstein P, Tiling R & Hacker M 2010 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptormediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. Journal of Nuclear Medicine 51 1349-1356. (doi:10.2967/jnumed.110.075002)
50. Hawkins DS, Conrad EU III, Butrynski JE, Schuetze SM & Eary JF 2009 [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer 115 3519-3525. (doi:10.1002/cncr.24421)
51. Hentic O, Couvelard A, Rebours V, Zappa M, Dokmak S,Hammel P, Maire F, O'Toole D, Lévy P, Sauvanet A et al. 2011 Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. Endocrine-Related Cancer 18 51-59. (doi:10.1677/ERC-09-0319)
52. Hiltermann TJN, Pore MM, van den Berg A, Timens W, Boezen HM, Liesker JJW, Schouwink JH, Wijnands WJA, Kerner GSMA, Kruyt FAE et al. 2012 Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Annals of Oncology 23 2937-2942. (doi:10.1093/annonc/mds138)
53. Hofland LJ, Lamberts SWJ, van Hagen PM, Reubi J-C, Schaeffer J, Waaijers M, van Koetsveld PM, Srinivasan A, Krenning EP & Breeman WAP 2003 Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs. Journal of Nuclear Medicine 44 1315-1321. (Pubitemid 39655192)
54. Hugonnet F, Fournier L, Medioni J, Smadja C, Hindié E, Huchet V, Itti E, Cuenod C-A, Chatellier G, Oudard S et al. 2011 Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study. Journal of Nuclear Medicine 52 1048-1055. (doi:10.2967/jnumed.110.084517)
55. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E & Oberg K 1997 Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Annals of Oncology 8 685-690. (doi:10.1023/A:1008215730767) (Pubitemid 27372168)
56. Jensen EH, Kvols L, McLoughlin JM, Lewis JM, Alvarado MD, Yeatman T, Malafa M & Shibata D 2007 Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Annals of Surgical Oncology 14 780-785. (doi:10.1245/s10434-006-9148-z) (Pubitemid 46175327)
57. Jensen KH, Hilsted L, Jensen C, Mynster T, Rehfeld JF & Knigge U 2013 Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors. Scandinavian Journal of Gastroenterology 48 70-77. (doi:10.3109/00365521.2012.733953)
58. Khan MS, Tsigani T, Rashid M, Rabouhans JS, Yu D, Luong TV, Caplin M & Meyer T 2011 Circulating tumor cells and EpCAM expression in neuroendocrine tumors. Clinical Cancer Research 17 337-345. (doi:10.1158/1078- 0432.CCR-10-1776)
59. Khan MS, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME & Meyer T 2012 Circulating tumor cells as prognostic and predictive markers in neuroendocrine tumors. Journal of Clinical Oncology 30 4123. (doi:10.1200/JCO.2011.38.7852)
60. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R & Yao JC 2004 Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. Journal of Clinical Oncology 22 4762-4771. (doi:10.1200/JCO.2004.04.024)
61. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO & Krenning EP 2008 Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]-octreotate: toxicity, efficacy, and survival. Journal of Clinical Oncology 26 2124-2130. (doi:10.1200/JCO.2007.15. 2553)
62. Lassau N, Chami L, Chebil M, Benatsou B, Bidault S, Girard E, Abboud G & Roche A 2011 Dynamic contrast-enhanced ultrasonography (DCE-US) and anti-angiogenic treatments. Discovery Medicine 11 18-24.
63. Lassau N, Chapotot L, Benatsou B, Vilgrain V, Kind M, Lacroix J, Cuinet M, Taieb S, Aziza R, Sarran A et al. 2012a Standardization of dynamic contrast-enhanced ultrasound for the evaluation of antiangiogenic therapies. Investigative Radiology 47 711-716. (doi:10.1097/RLI.0b013e31826dc255)
64. Lassau N, Vilgrain V, Taieb S, Lacroix J, Aziza R, Cuinet M, Soria J-C, Chapotot L & Koscielny S 2012b Evaluation with DCE-US of antiangiogenic treatments in 539 patients allowing the selection of one surrogate marker correlated to overall survival. Journal of Clinical Oncology 30 (Suppl) abstr. 4618.
65. Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B & Modlin IM 2011 The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America 40 111-134. (doi:10.1016/j.ecl.2010.12.001)
66. Lencioni R & Llovet JM 2010 Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in Liver Disease 30 52-60. (doi:10.1055/s-0030-1247132)
67. Liu K, Li G, Fan C, Zhou C & Li J 2012 Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy. Acta Radiologica 53 127-134. (doi:10.1258/ar.2011.110273)
68. Llovet JM, Ricci S, Mazzaferro V, Hilgard P,Gane E, Blanc J-F, de Oliveira AC, Santoro A, Raoul J-L, Forner A et al. 2008 Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 359 378-390. (doi:10.1056/NEJMoa0708857)
69. Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK & Ball DL 2003 Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-smallcell lung cancer. Journal of Clinical Oncology 21 1285-1292. (doi:10.1200/JCO.2003.07.054) (Pubitemid 46606405)
70. Marcus CD, Ladam-Marcus V, Cucu C, Bouché O, Lucas L & Hoeffel C 2009 Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Critical Reviews in Oncology/Hematology 72 217-238. (doi:10.1016/j.critrevonc.2008.07.012)
71. Marion-Audibert A-M, Barel C, Gouysse G, Dumortier J, Pilleul F, Pourreyron C, Hervieu V, Poncet G, Lombard-Bohas C, Chayvialle J-A et al. 2003 Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 125 1094-1104. (doi:10.1016/S0016-5085(03) 01198-3) (Pubitemid 37193456)
72. Matsusaka S, Chìn K, OguraM, Suenaga M, Shinozaki E,Mishima Y, Terui Y, Mizunuma N & Hatake K 2010 Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. Cancer Science 101 1067-1071. (doi:10.1111/j.1349-7006.2010. 01492.x)
73. Mitry E, Walter T, Baudin E, Kurtz JE, Ruszniewski P, Dominguez S, Bengrine-Lefevre L, Cadiot G, Kraemer S & Ducreux M 2012 Efficacy and safety of bevacizumab combined with capecitabine in progressive, metastatic well-differentiated digestive endocrine tumors (BETTER study). Journal of Clinical Oncology 30 (Suppl) 4071.
74. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV & Kidd M 2010 Chromogranin A-biological function and clinical utility in neuroendocrine tumor disease. Annals of Surgical Oncology 17 2427-2443. (doi:10.1245/s10434-010- 1006-3)
75. Montravers F, Kerrou K, Nataf V, Huchet V, Lotz J-P, Ruszniewski P, Rougier P, Duron F, Bouchard P, Grangé J-D et al. 2009 Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. Journal of Clinical Endocrinology and Metabolism 94 1295-1301. (doi:10.1210/jc.2008-1349)
76. Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle J-A, Penes M-C, Sassolas G & Borson-Chazot F 2004 Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clinical Endocrinology 60 644-652. (doi:10.1111/j.1365-2265.2004.02030.x) (Pubitemid 38669857)
77. Ng CS, Charnsangavej C, Wei W & Yao JC 2011 Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. American Journal of Roentgenology 196 569-576. (doi:10.2214/AJR.10. 4455)
78. Nilsson O 2013 Profiling of ileal carcinoids. Neuroendocrinology 97 7-18. (doi:10.1159/000343232)
79. O'Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O'Connor J, Pape U-F & Plöckinger U 2009 ENETS Consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers. Neuroendocrinology 90 194-202. (doi:10.1159/000225948)
80. Panzuto F, Falconi M, Nasoni S, Angeletti S, Moretti A, Bezzi M, Gualdi G, Polettini E, Sciuto R, Festa A et al. 2003 Staging of digestive endocrine tumours using helical computed tomography and somatostatin receptor scintigraphy. Annals of Oncology 14 586-591. (doi:10.1093/annonc/mdg160) (Pubitemid 41295088)
81. Paulson EK, McDermott VG, Keogan MT, DeLong DM, Frederick MG & Nelson RC 1998 Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology 206 143-150. (Pubitemid 28062998)
82. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM et al. 2011 Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378 2005-2012. (doi:10.1016/S0140- 6736(11)61742-X)
83. Peungjesada S 2013 Evaluation of cancer treatment in the abdomen: trends and advances. World Journal of Radiology 5 126-142. (doi:10.4329/wjr.v5.i3.126)
84. Pirker RA, Pont J, Pöhnl R, Schütz W, Griesmacher A & Müller MM 1998 Usefulness of chromogranin A as a marker for detection of relapses of carcinoid tumours. Clinical Chemistry and Laboratory Medicine 36 837-840. (doi:10.1515/CCLM.1998.147) (Pubitemid 28552124)
85. Piscaglia F, Nolsøe C,Dietrich C, CosgroveD,Gilja O, Bachmann Nielsen M, Albrecht T, Barozzi L, Bertolotto M, Catalano O et al. 2011 The EFSUMB guidelines and recommendations on the clinical practice of contrast enhanced ultrasound (CEUS): update 2011 on non-hepatic applications. Ultraschall in der Medizin 33 33-59. (doi:10.1055/s-0031-1281676)
86. Raymond E, Dahan L, Raoul J-L, Bang Y-J, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A et al. 2011 Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine 364 501-513. (doi:10.1056/NEJMoa1003825)
87. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS & Motzer RJ 2011 Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. Journal of the National Cancer Institute 103 763-773. (doi:10.1093/jnci/djr128)
88. Rodallec M, Vilgrain V, Couvelard A, Rufat P, O'Toole D, Barrau V, Sauvanet A, Ruszniewski P & Menu Y 2006 Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 6 77-85. (doi:10.1159/000090026)
89. Schott M, Klöppel G, Raffel A, Saleh A, Knoefel WT & Scherbaum WA 2011 Neuroendocrine neoplasms of the gastrointestinal tract. Deutsches Ärzteblatt International 108 305-312. (doi:10.3238/arztebl.2011.0305)
90. Seregni E, Ferrari L, Bajetta E, Martinetti A & Bombardieri E 2001 Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Annals of Oncology 12 (Suppl 2) S69-S72. (doi:10.1093/annonc/12.suppl- 2.S69)
91. Skougaard K, Nielsen D, Jensen BV & Hendel HW 2013 Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab. Journal of Nuclear Medicine 54 1026-1031. (doi:10.2967/jnumed.112.111757)
92. Smith IC,Welch AE, Hutcheon AW,Miller ID, Payne S, Chilcott F, Waikar S, Whitaker T, Ah-See AK, Eremin O et al. 2000 Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. Journal of Clinical Oncology 18 1676-1688. (Pubitemid 30220546)
93. Smith AD, Shah SN, Rini BI, Lieber ML & Remer EM 2010 Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. American Journal of Roentgenology 194 1470-1478. (doi:10.2214/AJR.09.3456)
94. Sun Y-S, Cui Y, Tang L, Qi L-P, Wang N, Zhang X-Y, Cao K & Zhang X-P 2011 Early evaluation of cancer response by a new functional biomarker: apparent diffusion coefficient. American Journal of Roentgenology 197 W23-W29. (doi:10.2214/AJR.10.4912)
95. Sundin A & Rockall A 2012 Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead. Neuroendocrinology 96 261-271. (doi:10.1159/000342270)
96. Suzuki C, Blomqvist L, Sundin A, Jacobsson H, Byström P, Berglund Å, Nygren P & Glimelius B 2012 The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Annals of Oncology 23 948-954. (doi:10.1093/annonc/mdr350)
97. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK et al. 2004 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101 1776-1785. (doi:10.1002/cncr.20585) (Pubitemid 39314740)
98. Taouli B & Koh D-M 2010 Diffusion-weighted MR imaging of the liver. Radiology 254 47-66. (doi:10.1148/radiol.09090021)
99. Teunissen JJM, Kwekkeboom DJ, Valkema R & Krenning EP 2011 Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocrine-Related Cancer 18 (Suppl 1) S27-S51. (doi:10.1530/ERC-10-0282)
100. Tsikitis VL, Wertheim BC & Guerrero MA 2012 Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a SEER analysis. Journal of Cancer 3 292-302. (doi:10.7150/jca.4502)
101. van der Veldt AAM,Meijerink MR, van den Eertwegh AJM, Haanen JBAG & Boven E 2010 Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. British Journal of Cancer 102 803-809. (doi:10.1038/sj.bjc.6605567)
102. Vezzosi D, Walter T, Laplanche A, Raoul JL, Dromain C, Ruszniewski P, d'Herbomez M, Guigay J,Mitry E, Cadiot G et al. 2011 Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study. International Journal of Biological Markers 26 94-101. (doi:10.5301/JBM.2011. 8327)
103. Vinik E, Silva MP & Vinik AI 2011 Measuring the relationship of quality of life and health status, including tumor burden, symptoms, and biochemical measures in patients with neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America 40 97-109. (doi:10.1016/j.ecl.2010.12.008)
104. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, De Cristoforo C et al. 2010 Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. European Journal of Nuclear Medicine and Molecular Imaging 37 2004-2010. (doi:10.1007/s00259-010-1512-3)
105. Wahl RL, Jacene H, Kasamon Y & Lodge MA 2009 From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. Journal of Nuclear Medicine 50 (Suppl 1) 122S-150S. (doi:10.2967/jnumed.108.057307)
106. Walter T, Chardon L, Chopin-laly X, Raverot V, Caffin A-G, Chayvialle J-A, Scoazec J-Y & Lombard-Bohas C 2012 Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours? European Journal of Cancer 48 1766-1773. (doi:10.1016/j.ejca.2011.11.005)
107. Wassermann J, Bouattour M, Bruno O, Serrate C, Larroque B, Castera L,
108. Welin S, Stridsberg M, Cunningham J, Granberg D, Skogseid B, Oberg K, Eriksson B & Janson ET 2009 Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 89 302-307. (doi:10.1159/000179900)
109. Wieder HA, Brücher BLDM, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ et al. 2004 Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. Journal of Clinical Oncology 22 900-908. (doi:10.1200/JCO.2004.07.122)
110. Yadegarfar G, Friend L, Jones L, Plum LM, Ardill J, Taal B, Larsson G, Jeziorski K, Kwekkeboom D & Ramage JK 2013 Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. British Journal of Cancer 108 301-310. (doi:10.1038/bjc.2012.560)
111. Yang Z, Tang LH & Klimstra DS 2011 Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. American Journal of Surgical Pathology 35 853-860. (doi:10.1097/PAS. 0b013e31821a0696)
112. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey J-N, Rashid A et al. 2008 One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology 26 3063-3072. (doi:10.1200/JCO.2007.15.4377)
113. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D et al. 2010a Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. Journal of Clinical Oncology 28 69-76. (doi:10.1200/JCO.2009.24.2669)
114. Yao JC, Phan AT, Fogleman D,Ng CS, Jacobs C, Dagohoy C, Leary C & Hess K 2010b Randomized run-in study of bevacizumab (B) and everolimus (E) in low-to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. Journal of Clinical Oncology 28 (Suppl) 4002.
115. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EGE et al. 2011a Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 364 514-523. (doi:10.1056/NEJMoa1009290)
116. Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A & Öberg KE 2011b Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. Journal of Clinical Endocrinology and Metabolism 96 3741-3749. (doi:10.1210/jc.2011-0666)
117. Yao JC, Hainsworth JD, Wolin EM, Pavel ME, Baudin E, Gross D, Ruszniewski P, Tomassetti P, Panneerselvam A, Saletan S et al. 2012a Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (ECO) or placebo (PCO) among patients with advanced neuroendocrine tumors (NET). Journal of Clinical Oncology 30 (Suppl) abstr 4014.
118. Yao JC, Shah M, Panneerselvam A, Stergiopoulos S, Chen D, Ito T, Pavel M, Faivre S, Niccoli P, Raoul JL et al. 2012b The VEGF pathway in patients with pancreatic neuroendocrine tumors: efficacy of everolimus by baseline marker level, and prognostic and predictive effect analyses from RADIANT-3. Annals of Oncology 23 ix376. (doi:10.1093/annonc/mds405)
119. ZatelliMC, Torta M, Leon A,Ambrosio MR, GionM, Tomassetti P, Braud FD, Fave GD, Dogliotti L & Uberti EC degli 2007 Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocrine-Related Cancer 14 473-482. (doi:10.1677/ERC-07-0001)
120. Ziai D, Wagner T, El Badaoui A, Hitzel A, Woillard JB, Melloni B &Monteil J 2013 Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria. Cancer Imaging 13 73-80. (doi:10.1102/1470-7330.2013.0008)